Screener
Sutro Biopharma STRO Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $54.34M-15.1% | $73.68M-30.6% | $58.13M-69.5% | $65.93M-62.2% | $64.03M-29.5% | ||
| $110.01M-22.0% | $128.88M-9.7% | $83.3M-34.2% | $101.67M-52.4% | $141.11M-50.5% | ||
| $5.8M-27.5% | $12.48M-7.9% | $3.98M-53.8% | $3.92M-41.1% | $8M+15.1% | ||
| $175.65M-24.2% | $220.97M-23.1% | $150.93M-56.0% | $182.11M-55.1% | $231.63M-47.8% | ||
| $8.36M-44.2% | $9.36M-44.3% | $10.65M-41.5% | $13.35M-29.7% | $14.98M-22.8% | ||
| $194.46M-25.9% | $241.99M-24.7% | $173.83M-55.1% | $209.66M-53.6% | $262.36M-46.4% | ||
| $3.36M-22.1% | $5.49M-32.9% | $7.57M-27.8% | $7.03M+13.2% | $4.31M-29.2% | ||
| $6.46M-46.0% | $9.4M-86.4% | $10.56M-84.9% | $8.98M-87.6% | $11.96M-83.8% | ||
| $52.9M-28.8% | $70.81M-46.8% | $75.13M-43.0% | $71.9M-45.2% | $74.25M-42.9% | ||
| $297.78M+1.1% | $308.88M-11.0% | $306.28M-10.6% | $296.93M-12.8% | $294.47M-12.6% | ||
| $17K-80.0% | $17K-79.8% | $9K+12.5% | $85K+3.7% | $85K+3.7% | ||
| -$1.05B-20.7% | -$1.02B-17.8% | -$977.96M-24.3% | -$931.19M-30.3% | -$874.34M-31.4% | ||
| -$103.32M-222% | -$66.89M-159% | -$132.45M-397% | -$87.27M-178% | -$32.11M-121% | ||
| $194.46M-25.9% | $241.99M-24.7% | $173.83M-55.1% | $209.66M-53.6% | $262.36M-46.4% |
FAQ
- What are Sutro Biopharma's total assets?
- Sutro Biopharma (STRO) holds $194.5M in total assets, down 25.9% year over year.
- How much debt does Sutro Biopharma have?
- Sutro Biopharma carries $10.8M in total debt against -$103.3M of shareholders' equity, a debt-to-equity ratio of 0.52.
- How much cash does Sutro Biopharma have?
- Sutro Biopharma holds $54.3M in cash and equivalents.
- Can Sutro Biopharma cover its short-term obligations?
- Its current ratio is 3.32 — current assets exceed current liabilities.
- Where does Sutro Biopharma's balance sheet data come from?
- Every line is extracted from Sutro Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
